Lung adenocarcinoma (LADC), the most prevalent type of human lung cancer, is characterized by many molecular abnormalities. SH2B1, a member of the SH2-domain containing family, have recently been shown to act as tumor activators in multiple cancers, including LADC. However, the mechanisms underlying SH2B1 overexpression are not completely understood. Here, we reported that SH2B1 expression levels were significantly upregulated and positively associated with EMT markers and poor patient survival in LADC specimens. Modulation of SH2B1 levels had distinct effects on cell proliferation, cell cycle, migration, invasion, and morphology in A549 and H1299 cells in vitro and in vivo. At the molecular level, overexpression of SH2B1 resulted in the upregulation of the EMT markers, especially induced β-catenin accumulation and activated β-catenin signaling to promote LADC cell proliferation and metastasis, while silencing SH2B1 had the opposite effect. Furthermore, ectopic expression of SH2B1 in H1299 cells increased IRS1 expression level. Reduced expression of IRS1 considerably inhibited H1299 cell proliferation, migration, and invasion which were driven by SH2B1 overexpression. Collectively, these results provide unequivocal evidence to establish that SH2B1-IRS1-β-catenin axis is required for promoting EMT, and might prove to be a promising strategy for restraining tumor progression in LADC patients.
| INTRODUCTION
Lung cancer occupies a peculiar place in the public mind and contributes substantially to the global cancer burden and healthcare costs both in the United States and in China. [1] [2] [3] Owing to fail the initial therapy and lack of effective treatment for advanced lung cancer, even if decades of extensive studies, the prognosis remains poor with approximately 15-18% of 5-year relative survival rates. 1, 4 A multistage GWAS (genome-wide association studies) on lung cancer suggested that lung tumors attributed to differing carcinogens may have developed from individual genetic risk markers. 4 And most notably, lung adenocarcinoma (LADC), the most frequent histological type of lung cancer, has exploited and elevated the clinical application of effective molecular targeted therapies. 5, 6 The effectiveness of precision medicine against LADCs urgently requires peculiar molecular markers and novel therapeutic strategies from vast changes in gene regulation.
The SH2B1 (Src homology 2 [SH2] B adaptor protein 1) gene maps to the chromosomal region 16p11.2, which microdeletion is frequently associated with developmental delay, congenital anomalies and obesity. 7 SH2B1 is a member of the SH2B adaptor proteins family, mainly characterized by an SRC homology 2 (SH2), a pleckstrin homology domain (PH), and phenylalanine zipper dimerization domain (DD). 8 And so SH2B1 performs classical adaptor functions to recruit specific proteins, but, it also has a unique ability to enhance cytokine receptor-associated tyrosine kinases (eg, JAK kinase) and several receptor tyrosine kinase activity, 9 including the receptors for insulin, 10 insulin-like growth factor (IGF-1), 11 fibroblast growth factor (FGF), 12 glial cell line-derived neurotrophic factor (GDNF), 13 plateletderived growth factor (PDGF), 14 brain-derived neurotrophic factor (BDNF), 15 and nerve growth factor (NGF). 16 Cells often employ SH2B1 to connect signal proteins to achieve accurate and appropriate cellular responses from external environmental stimuli, that is termed as signal transduction and signal enhancement processes. 9 Both in central nervous system and in peripheral tissues, SH2B1 is widely expressed and systemic changes in SH2B1 expression, dominantly deletion mutation, could have profound effects to result in energy imbalance, obesity, severe leptin resistance, and type 2 diabetes in mice and humans. 17 Clinical importance for the field of SH2B1 research is not only focused on endocrine disease, 18, 19 but also concerned with some solid tumors, including lung cancer, 20, 21 esophageal cancer, 22 and thyroid carcinomas, 23 which detected somatic gain-of-function mutations. In addition, emerging several lines of basic research in cultured cells show that the function of SH2B1 is involved in actin cytoskeletal reorganization, 24, 25 focal adhesion assembly and disassembly, 26 filopodium formation, 27, 28 and mitogenic response, 29 suggesting that SH2B1 could regulate cells motility, 24, 30 proliferation and differentiation 17, 29 by enhancing Rac, 30 RET, 23 mTOR, 31 and STATs 29 signals, which are generally established mediators in tumorigenesis and EMT program in tumors. [32] [33] [34] [35] The epithelial to mesenchymal transition (EMT), as a spectrum of intermediate states between the epithelial and mesenchymal phenotypes, plays crucial roles in epithelial-derived neoplasia and tumor invasiveness and metastasis 36, 37 by modifying adhesion molecules proteins to trigger cancer cells dissociation to adopt a migratory and invasive behavior. A key inducer of EMT is the canonical Wnt signal through β-catenin dependent, which implies its significance in maintaining an epithelial cell phenotype, proper cell-cell junctions, cell differentiation, and proliferation in a subset of cancer. 37, 38 Intriguingly, insulin receptor substrates-1 (IRS1), have been identified as a major player in the regulation of Wnt-mediated EMT. 39 We previously determined that SH2B1 directly bound, via its PH and SH2 domain, to IRS1 to activate PI3-kinase pathway. 40 However, the roles of SH2B1 in LADC are poorly understood. In this study, SH2B1 is substantially overexpressed in clinical LADC and significantly correlated with poor patient prognosis. We first demonstrate that SH2B1
promoted cell migration and induction of EMT in response to Wnt stimulation, whereas depletion of IRS1 impaired the SH2B1-mediated cell migration and EMT phenotype of LADC both in vitro and in vivo.
Our findings uncover that a novel SH2B1-IRS1-β-catenin axis is required for promoting EMT, and might prove to be a promising strategy for restraining tumor progression in LADC patients. 
| MATERIALS AND METHODS

| Ethical statement
| Immunohistochemistry
IHC analysis was performed on the 159 paraffin-embedded LADC tissue sections, using the following primary antibodies, anti-SH2B1
(1:100, ab196575, Abcam), anti-E-cadherin (1:500, ab40772, Ab- 
| Xenografted tumor model and H&E staining
Male BALB/c-nu mice (age of 4-5weeks, 16-18g) were purchased from the Hunan Slack King of Laboratory Animal Co., Ltd (Changsha, China).
Mice were randomly divided into groups (n = 5 per group) before injection. The invasion effect of SH2B1 on LADC progression was examined in a lung colonization model. 42 Two groups were injected with shSH2B1 transduced A549 cells or control A549 cells (1 × 10 6 cells in 0.1 ml phosphate-buffered saline) via lateral tail veins. Another two groups were intravenously injected with stable SH2B1-overexpressing or control H1299 cells. Mice were killed 60 days after injection, and lungs were collected to performed to H&E staining.
| Western blotting
Western blotting was performed using the primary antibodies, anti- D110016, Sangon Biotech, Shanghai, China). Following the Western blotting assay, the membranes were stripped, and the band intensities were relative to GAPDH. The quantification of protein bands was performed using ImageJ software.
| Immunofluorescent staining
Cells seeded on a coverslip were fixed in 4% paraformaldehyde for 15 min, DAPI (4,6-diamidino-2-phenylindole, hoechst33342, C1026, Beyotime
Biotechnology, Shanghai, China) were used for nuclear staining. Images were captured by fluorescent microscopy.
| In vitro migration and invasion assay
For wound healing assay, monolayer cells were grown in six-well plates without creating any scratch-wound until confluency. Cells migration was observed and measured the width of a wound by microscopy 24 h later.
For transwell assays using polycarbonate transwell filters containing 8 µm pores (#3422, Corning coster, Cambridge, MA), cells
/100 µl) were plated in serum-free medium on the top chambers that was either uncoated, for the migration assay, or coated with Matrigel (BD Biosciences, Bedford, MA) for the invasion assay.
The bottom chamber added 600 µl medium containing 10% fetal bovine serum. After 48h of incubation, the inserts were washed with PBS, and migrated cells were fixed, stained and then counted from six random fields. Experiments were performed in triplicate.
| Statistical data analysis
All statistical analyses in this study were carried out using SPSS (Table 2) .
Given the higher levels of SH2B1 in LADC patients, we investigated whether SH2B1 correlated with patient survival. The 159 patients were divided into two groups using the IHC staining index (SI = 8) of SH2B1 as the cut-off value (negative: SI < 8; positive: SI ≥ 8).
A threshold of 5-year follow-up revealed that patients with higher SH2B1 protein level had significantly shorter overall survival (P < 0.001, Figure 1C ) and poor disease-free survival (P < 0.001, Figure 1D ) compared with that of LADC patients with lower SH2B1 protein expression.
| Increased SH2B1 expression level is associated with EMT-related proteins in human LADC
The epithelial-mesenchymal transition (EMT) have been identified as crucial drivers of tumor progression and contributed to metastatic colonization. 36 In the last decade, more studies have still been focused on and further fueled the interest in EMT in the cancer field, especially the clinical significance of partial EMT. 36 Given the wide range of SH2B1 roles in cell motility, 24, 30 we firstly raised the clinical question whether there existed associated relationship among the expression levels of SH2B1 and EMT-related proteins, such as E-cadherin, N-cadherin, Vimentin, and β-catenin. 43 To validate the connection in a larger cohort of LADC patients, we performed immunohistochemistry (ICH) staining in 159 paired LADC tumors and adjacent normal lung tissues obtained from Xiangya Hospital Thoracic Tissue Bank.
Representative pictures were depicted in Figure 2A . (Table 2 ). There were close relationships between SH2B1 or EMT-related proteins and LADC clinical stages. As shown in Table 2 , compared with stages I and II, advanced LADC (stages III and IV)
showed a significantly decreased E-cadherin (28.85% vs 70.09%, P = 0.000) and increased SH2B1 (54.21% vs 75.00%, P = 0.012), N-cadherin (77.57% vs 92.31%, P = 0.022), Vimentin (61.68% vs 82.68%, P = 0.007), and β-catenin (76.64% vs 86.54%, P = 0.028) expression. Furthermore, the expression levels of SH2B1 were negatively associated with E-cadherin expression but positively correlated with that of N-cadherin, Vimentin, and β-catenin expression in LADC cancer tissues ( Figure 2B ).
| SH2B1 alters EMT markers and induces the EMT phenotypes of LADC cells
A genetic EMT signature was common to various cancers. 44 Given that the wide range of EMT status in our clinical LADC specimens, the maintenance or loss of epithelial and mesenchymal markers was a good indicator of a potential EMT in LADC cell lineage analysis. We cells also affected the expression of EMT markers, resulting in E-cadherin downregulation and mesenchymal markers upregulation ( Figure 3C ).
We further studied whether SH2B1 had an active role in the promotion of LADC cells migration and invasiveness. To test this, using transwell migration and invasion assays, we observed SH2B1-knockdown significantly held back the cells migration and suppressed invasion ( Figure 3D ) of A549 cells. In line with this, elevated migration and invasion was seen in H1299-SH2B1 cells ( Figure 3E ). 
| SH2B1 promotes EMT in LADC cells through the wnt/β-catenin pathway
Given that β-catenin expression was related to TNM stages of LADC 
| SH2B1 regulates wnt/β-catenin signaling through IRS1
SH2B1 has been reported to recruit and directly bind to insulin receptor substrates (IRS-1, -2, -3 and -4), particularly IRS1 in HEK293 cells. 9 The physical SH2B1-IRS1 interaction could inhibit tyrosine dephosphorylation of IRS1 and promote IRS1 proteins to active the phosphatidylinositol 3-kinase (PI3-K)/Akt pathway, 40, 48 which has been emerging as a central feature of EMT. 49 Most importantly, it has been identified that IRS1 was a significant active player in the regulation of EMT 50 in response to Wnt/β-catenin signals by which interacted with and stabilized DVL2, a hub of Wnt signaling, via suppressing its autophagic degradation. 39, 51 In the same clinical cohort study, IHC analysis revealed that IRS1 expression positively correlated with SH2B1 expression (P < 0.001, Figure 5A ). In LADC cells ( Figure 5B and N-cadherin decreased, while E-cadherin increased. ( Figure 5C ).
Importantly, depletion of IRS1 blocked the effect of SH2B1 induced cell migration and invasion ( Figures 5D and 5E ). These data suggested that depletion of IRS1 inhibited the Wnt/β-catenin signaling induced by SH2B1.
| DISCUSSION
Advanced LADC patients who miss the optimal opportunity of surgery have limited therapeutic options in the clinic at present. Hence, urgent priority is to accelerate progress toward investigating biological basis and identifying novel targets for LADC prevention and therapy. 52 In this study, we firstly identified SH2B1 to be highly expressed in LADC patients and functionally required for EMT phenotype by positively regulating Wnt/β-catenin signaling. Intriguingly, we also found that SH2B1 could activate IRS1 to promote Wnt/β-catenin pathway.
Therefore, our findings revealed that SH2B1 was verified to play a critical role in LADC progression.
During epithelial-derived carcinomas progression, EMT and intermediate states, highly dynamic and plastic manners, endow cells with migratory and invasive properties by modifying the adhesion molecules. 36 As such, E-cadherin is the most commonly used marker for the epithelial trait, while N-cadherin, vimentin, and β-catenin are for mesenchymal to confirm EMT. 43 However, even though EMT processes have been documented in many cancer cell models in vitro, considerably more important are the convincing evidence of EMT in cancer progression by direct imaging in vivo 53 and its relevance in human cancer tissues. 49 In this study, we collected cancer samples from edge of human lung adenocarcinomas because morphological evidence of EMT 54 and some focal events were mainly executed at tumor edges. 36 Our results demonstrated that EMT markers changes were all correlated with clinical stages of LADC patients, suggesting that our findings were in agreement with recent studies highlighting the importance of EMT status in conferring tumor progression in cancer. 44 Given the existence of EMT gradients in conjunction with LADC intrinsic molecules, such as the EGFR mutation 55 or ALK fusion transcript status, 56 we have yet to determine how far SH2B1 should Furthermore, in the presence of cell lineage analyses, the EMT program was observed in migrating cells with mesenchymal morphology and more filopodia structures. 58 Interestingly, SH2B1 promoted filopodium formation and increased the number of filopodia. 28 We observed that SH2B1 overexpression promoted, whereas SH2B1 knockdown impeded, cell morphological changes from a cobblestonelike to spindle shape accompanying with the alteration of EMT markers. Collectively, these in vitro and in vivo data indicate that SH2B1 was a better oncogene and promoted EMT.
Wnt/β-catenin alterations are prominent in human lung cancer and substantially impact tumorigenesis, prognosis, and resistance to therapy. 45 Wnt signals have been reported to regulate EMT program and cell proliferation. 59 As noted previously, β-catenin was higher signaling pathways. 60 Consistent with this, some miRNAs mediate proliferation and metastasis of cancer cells through targeting IRS1. 61, 62 Recently, Geng et al 51 reported that IRS1 could promote Wnt-mediated EMT and cell proliferation by interacting with and stabilizing Dvl2.
Besides, our previous study in the SH2B1 knockout mice indicated that SH2B1 could interact with IRS1 and lead to intracellular cascades transduction, such as the activation of the Erk1/2 and PI 3-kinase pathways. 40, 63 Constitutive activation of IRS1 is found in some solid human tumors. 64, 65 In this study, we provide evidence that depletion of IRS1 inhibited SH2B1-overexpression-induced cell invasion and metastasis and uncovered that IRS1 has the positive effect on SH2B1-mediated Wnt signals activation. On the other hand, apart from Wnt/β-catenin signaling, SH2B1/IRS1 also active other pathways, including
Erk1/2 and PI3-kinase. Therefore, these results provide an impetus to investigate a possible cross-talk between enhanced SH2B1-induced signal transduction pathways regarding the role of SH2B1 in EMT.
In conclusion, our findings reveal that SH2B1 has a major role in LADC progression and that SH2B1 is a critical activator of Wnt/β-catenin signaling. Understanding the precise function of SH2B1 in the pathogenesis of LADC and activation of the SH2B1-IRS1-β-catenin axis will extend our knowledge of the biological basis of LADC progression and may also offer new insight into a new therapeutic target, enhancing the clinical benefits of LADC patients.
